Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured

Published in Bladder Cancer and

Journal Scan / Research · January 18, 2023

Oncologic Outcomes of Neoadjuvant Chemotherapy in Patients With Micropapillary Variant Urothelial Carcinoma of the Bladder

Urologic Oncology: Seminars and Original Investigations

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Kelly Stratton MD

Urologic Oncology: Seminars and Original Investigations

Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder

Urol. Oncol 2022 Dec 05;[EPub Ahead of Print], SN Rahman, SD Lokeshwar, JS Syed, JF Javier-Desloges, BH Press, AU Choksi, P Rajwa, B Pradere, G Ploussard, JW Kim, TF Monaghan, JR Renzulli, SF Shariat, MS Leapman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Bladder Cancer

Oncologic Outcomes of Neoadjuvant Chemotherapy in Patients With Micropapillary Variant Urothelial Carcinoma of the Bladder

Additional Info

Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder

Further Reading

Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma

Safety and Efficacy of WST-11 (TOOKAD Soluble) Vascular-Targeted Photodynamic Therapy in Patients With UTUC

NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer

Role of Cell-Free Urine and Plasma DNA Mutation Analysis in Predicting Neoadjuvant Chemotherapy Response and Outcomes in Patients With MIBC

DFS Analysis in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma Using PD-L1 Combined Positive Score and Tumor Cell Score

AI-Based Model for Detecting Lymph Node Metastases in Patients With Bladder Cancer

Assessment of Survival Advantage of Radical Cystectomy in Patients With Adenocarcinoma of the Bladder vs Urothelial Bladder Cancer

Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Therapy vs BCG Therapy in Patients With High-Risk Non–Muscle-Invasive Bladder Cancer

Outcomes of En Bloc Resection vs Conventional TURBT in Patients With T1 High-Grade Bladder Cancer

Efficacy of High- and Low-Dose Preoperative Ipilimumab Plus Nivolumab in Patients With Stage III Urothelial Cancer

Recently Updated